Easyef(Ingredient: EGF) With Excellent Effect Upon Treatment Of Chronic Injury And Scar Inhibition
 
Easyef Jordan Launching Symposium 
Acceleration of advance into foreign market with Easyef

Daewoong Pharmaceutical’s Jordan Launching Symposium for Easyef(ingredient: EGF) was successfully held in Amman on May 5th,, where 100 physicians specializing in injuries in the Middle East participated. Easyef is the domestic first biodrug, which processed EGF, internal injury-healing substance, into drug for the first time in the world.

This symposium is highly meaningful in that such domestic first biodrug entered into foreign market for the first time and at the same time secured a footing to make a criterion for world-class injury therapy with EGF, internal injury-healing substance.
In this symposium, Dr. Park Seung Guk, Easyef’s developer of Daewoong Pharmaceutical introduced Easyef, professor Yu Dae Hyeon(Department of Plastic Surgery, Yonsei University) conducted presentation under the subject of 'Therapy of skin injury with Easyef for immuno-deficient patients' and prof. Hong Jun Pyo(Department of Surgery, University of Ulsan College of Medicine) under the subject of 'Therapy of chronic injury with Easyef.’

Professor Yu Dae Hyeon announced "As a result of treatment with Easyef, excellent effect was found upon immunodeficiency due to kidney transplantation and chronic injury owing to diabetes  in addition to chemical therapy for a burn including radiation therapy,“ and ”Especially, the potential of Easyef to inhibit a scar from formation was found,” stirring up participants’ great interest.

Next speaker prof. Hong Jun Pyo said "As a result of comparison between administered group and non-administered group of the degree of scar healing on the 30th day after administration of Easyef into the pig’s skin scar, administered group showed 2 times faster treatment effect than non-administered group(administered group: about 65%, non-administered group: 30%), " and "Easyef displayed remarkable treatment effect in cases where infection was controlled and granulation tissue remained on the scar in treatment of severe diabetic foot ulcer that had not been healed for several years.” 

Easyef is domestic first biodrug which processed EGF, internal injury-healing substance, into drug for the first time in the world through research over 10 years from 1991. It is expected that Easyef will be used as therapy for a range of injuries including diabetic ulcer, burn, bedsore and chronic injuries due to immunodeficiency. 

Daewoong Pharmaceutical concluded Easyef Middle East distribution agreement with HIKMA, the Jordan top pharmaceutical company in 2002 and started export from the beginning of Ap. this year through item approval. Sales of USD 10 million including prepaid technical fee are expected for further 5 years. Beyond export to the Middle East area, Daewoong Pharmaceutical is actively preparing for export to China and other Southeast Asia areas. Also, it is promoting Easyef licensing toward the US, Europe and Japan.